AstraZeneca reported a 23 per cent increase in third-quarter net profit, supported by strong sales of its cancer medicines, as the British pharmaceutical company announced plans to save $1.5 billion annuAstraZeneca Third-Quarter Profit Jumps 23% as Drugmaker Plans $1.5 Billion in Annual Savings

ally and reinvest the funds in developing new treatments.

The company said on Friday that profit after tax reached $3.12 billion for the July to September period, compared with the same quarter a year earlier. The increase marked a stronger performance than the previous quarter, when net profit rose just over 2 per cent.

Revenue increased 7 per cent to $16.2 billion, while core earnings per share rose 17 per cent to $2.79. The earnings figure excludes certain items, including restructuring costs and the amortisation of acquired medicines.

Oncology remained AstraZeneca’s largest business, accounting for 48 per cent of total revenue. Sales in the division increased 17 per cent to $7.8 billion, supported by demand for lung cancer treatment Tagrisso and immunotherapy Imfinzi.

The company’s new cost-saving programme, named Reshaping for Sustainable Growth, is expected to generate $1.5 billion in annual savings. AstraZeneca said the funds would mainly support its research and development pipeline, which includes more than 180 projects.

The restructuring is expected to involve one-off charges of up to $2 billion and is scheduled to be largely completed by the end of 2029. The company did not announce any job cuts, although the changes could affect its workforce as resources are redirected across the business.

Chief Executive Pascal Soriot said AstraZeneca remained on course to achieve its long-term growth ambitions, pointing to late-stage drug candidates and the expansion of new technologies.

Pressure from generic medicines and China

The company’s growth came despite declining sales of some established medicines. Revenue from Farxiga, used to treat diabetes, heart and kidney disease, fell 25 per cent to $1.6 billion after generic alternatives entered the US market. Blood thinner Brilinta has also faced competition following the loss of patent protection.

AstraZeneca is also dealing with China’s volume-based procurement system, under which state purchasing programmes secure large orders from pharmaceutical companies in exchange for lower prices.

The drugmaker maintained its 2026 financial outlook, forecasting revenue growth in the mid-to-high single digits and an increase in core earnings per share in the low double digits, excluding currency movements.

It also reaffirmed its ambition to generate $80 billion in annual revenue by 2030, compared with nearly $59 billion in 2025. The company expects the US market to account for half of that target.

AstraZeneca has expanded its focus on the US, adding a direct share listing in New York in February, while also pledging to invest $15 billion in China by 2030.

The company said it had recorded 12 positive late-stage clinical trial results so far this year. Its development programme also includes a weight-loss treatment intended to compete with products such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.

AstraZeneca shares rose more than 4.5 per cent in early trading on Friday following the results.

South Korea has fined Google and Apple a combined 63.7 billion won (€42.7 million) for allegedly pressuring app developers to use their payment systems and delaying app reviews, adding to regulatory challenges facing the US technology companies over their app store practices.

The Korea Media and Communications Commission (KMCC) announced the penalties on Wednesday following an investigation launched in August 2022. Google was fined 42.9 billion won (€28.7 million), while Apple received a penalty of 20.8 billion won (€13.9 million).

The regulator found that both companies had violated a 2021 South Korean law prohibiting app store operators from forcing developers to use specific payment systems. South Korea was the first country to introduce such a rule.

Although Google and Apple allowed developers to offer alternative payment options within their apps, the commission said the companies charged a 26% commission on those transactions, only slightly below the 30% charged for payments through their own systems. The regulator also found that restrictions on certain features limited developers’ ability to use alternative payment services effectively.

Payments made through external websites were blocked altogether, according to the commission.

The investigation also found that both companies delayed app reviews without providing developers with adequate explanations or clear information about when the reviews would resume.

Apple was separately found to have charged South Korean developers more than developers in other markets between 2015 and January 2023. The commission said Apple calculated its commissions using prices that included value-added tax, increasing the amounts charged to local developers.

Under the latest ruling, both companies must allow South Korean developers to include links to external payment options in their apps and improve their app review procedures. They have one month to submit compliance plans and three months to implement the required changes.

Commission chairman Kim Jong-cheol said he hoped the sanctions would bring meaningful changes to the market. He added that South Korean law would be enforced equally against domestic and foreign companies.

Neither Google nor Apple had publicly commented on the decision at the time of the announcement.

The penalties follow similar regulatory action in the European Union, where the Digital Markets Act (DMA) restricts major online platforms from preventing developers from directing customers towards alternative purchasing options.

In April 2025, the European Commission fined Apple €500 million for breaching the DMA by restricting developers from steering users to cheaper offers outside its App Store. Apple appealed the decision.

The company subsequently announced revised terms for its European operations, effective October 1, reducing its standard commission on in-app purchases to 26% from 30% and introducing a 15% rate for purchases completed elsewhere after users were directed outside the app.

Google also faced a €890 million fine from Brussels in July, including €430 million linked to restrictions on developers using Google Play to direct customers towards cheaper purchasing options. Google has appealed the penalties and revised some of its fees and terms, which the European Commission is still assessing.

The South Korean decision underscores growing international scrutiny of app store business models, particularly the fees and restrictions imposed on developers seeking alternatives to platform-owned payment services.

BNP Paribas, France’s largest bank, reported stronger-than-expected third-quarter profits on Wednesday as a sharp increase in equities trading revenue boosted earnings, prompting the lender to announce a €1.3 billion share buyback while playing down its exposure to French government debt.

Net income rose 13.5% from a year earlier to €3.46 billion, exceeding the average analyst forecast of €3.23 billion, according to estimates compiled by the bank. Revenue increased 9.5% to €13.76 billion.

The strongest performance came from corporate and institutional banking, where revenue climbed 16.6% to €5.2 billion. Within that division, global markets revenue rose 21.9% to €2.67 billion, approaching the record level recorded in the first quarter.

Equity and prime services revenue surged 50% to €1.46 billion, reflecting stronger activity in share trading and services provided to hedge funds, including lending and clearing. Revenue from fixed income, currencies and commodities trading remained broadly unchanged at €1.22 billion, as growth in Asia and foreign exchange offset weaker performance in credit and interest rate markets.

“The Group achieved a very strong third quarter driven by the operating performance across all three divisions,” chief executive Jean-Laurent Bonnafé said.

Revenue from commercial and personal banking and services, which serves households and businesses, increased 3.6%, supported by interest rate conditions and higher fees.

However, the bank’s car leasing operations faced pressure. Revenue at Arval and Leasing Solutions fell 29.1% as used-car prices declined.

BNP Paribas set aside €964 million for potential loan losses during the quarter, equivalent to 39 basis points of customer loans. That remained within its 2026 target of keeping the cost of risk below 40 basis points.

The bank’s Common Equity Tier 1 capital ratio, a key measure of financial resilience, stood at 12.9% at the end of September. BNP expects the ratio to exceed 13% by year-end, supported by the sale of its Moroccan subsidiary BMCI.

The €1.3 billion buyback, approved by the European Central Bank, is scheduled to begin in November ahead of the distribution of profits for 2026.

BNP reaffirmed its financial targets through 2028, including a return on tangible equity of 12% this year and more than 13% in 2028. It plans to present a new strategic plan covering the period to 2030 on February 2. Its shares were down about 1.5% at the opening in Paris on Wednesday.

The results came amid concerns over France’s public finances and political uncertainty. BNP said it held approximately €19 billion in French government bonds, with about €16 billion accounted for at amortised cost, limiting the effect of market price fluctuations on capital.

The bank estimated that a further 0.5-percentage-point widening in the yield spread between French and German government bonds would reduce its capital ratio by only around 0.02 percentage points.

France accounted for less than 10% of BNP Paribas’ pre-tax income in 2025, compared with roughly half that proportion in 2016, reflecting the bank’s broader international diversification.